Supplementary Figure 4. gH mAbs are specific for HCMV neutralization. Neutralization of HSV-1 US-11 GFP (MOI 0.01) using anti-gH mAbs (50-0.016 ug/mL) and assessed usingGFP as a readout for infection
A safe, efficacious vaccine is required to stop the AIDS pandemic. Disappointing results from the STEP trial implied a need to include humoral anti-HIV-1 responses, a notion supported by RV144 trial d
A summary of geometric mean titers of PRNT50 GMT for comparison between the two ZIKV strains, MR-766 and FSS 13025 for both vaccine and virus control groups. Neutralizing activity elicited by the VLP
